Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
EFFECTS OF L-HISTIDINOL ON THE ANTITUMOR-ACTIVITY AND ACUTE CARDIOTOXICITY OF DOXORUBICIN IN MICE
Autore:
ALSHABANAH OA; BADARY OA; ALGHARABLY NM; ALSAWAF HA;
Indirizzi:
KING SAUD UNIV,COLL PHARM,DEPT PHARMACOL,POB 2457 RIYADH 11451 SAUDI ARABIA
Titolo Testata:
Pharmacological research
fascicolo: 3, volume: 38, anno: 1998,
pagine: 225 - 230
SICI:
1043-6618(1998)38:3<225:EOLOTA>2.0.ZU;2-H
Fonte:
ISI
Lingua:
ENG
Soggetto:
EXPERIMENTAL CANCER-CHEMOTHERAPY; ANTICANCER DRUGS; ADRIAMYCIN; AGENTS; ANTHRACYCLINES; COMBINATION; EFFICACY; HEART; RAT; SELECTIVITY;
Keywords:
L-HISTIDINOL; DOXORUBICIN; ANTITUMOR ACTIVITY; CARDIOTOXICITY; MICE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
35
Recensione:
Indirizzi per estratti:
Citazione:
O.A. Alshabanah et al., "EFFECTS OF L-HISTIDINOL ON THE ANTITUMOR-ACTIVITY AND ACUTE CARDIOTOXICITY OF DOXORUBICIN IN MICE", Pharmacological research, 38(3), 1998, pp. 225-230

Abstract

L-Histidinol (LHL), a structural analogue of the essential amino acidL-histidine, can improve the therapeutic index of antimetabolites andalkylating agents. The objective of the study was to determine whether LHL would modulate the antitumour activity and acute cardiotoxicity of the anthracycline antibiotic, doxorubicin (DOX). LHL (1.0 mM) potentiated the cytotoxicity of DOX (0.05-0.8 mu g ml(-1)) in cultured Ehrlich ascites carcinoma (EAC) cells. LHL (250 mg kg(-1), i.p.) administered for five consecutive doses at 2-h intervals starting 2 h before DOX (5 mg kg(-1), i.p.) single injection, enhanced the antitumour activity of DOX in EAC-bearing mice as manifested by a significant increase in average life span and cure rate of mice. In normal mice, LHL, in the same dose regimen, could not alter the acute cardiotoxicity and lethality of DOX (10 mg kg(-1), i.p.). The present data indicate that LHL may improve the therapeutic efficacy of DOX in EAC-bearing mice without compromising its toxicity. Also, our finding supports the LHL/anticancer drug combination approach. (C) 1998 The Italian Pharmacological Society.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/09/20 alle ore 13:14:49